1,087 results on '"Bioulac‐Sage, Paulette"'
Search Results
2. Structure, Function and Responses to Injury
3. The enigma of glutamine synthetase and b-catenin expression in hepatocellular adenoma in familial adenomatous polyposis coli
4. Assessment of a multivariable model using MRI-radiomics, age and sex for the classification of hepatocellular adenoma subtypes
5. Loss of RND3/RHOE controls entosis through LAMP1 expression in hepatocellular carcinoma
6. Spatial characterisation of β-catenin-mutated hepatocellular adenoma subtypes by proteomic profiling of the tumour rim
7. Antagonism between wild-type and mutant β-catenin controls hepatoblastoma differentiation via fascin-1
8. Author response: Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
9. Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
10. Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma
11. Emerging role of oncogenic ß-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
12. Emerging role of oncogenic ß-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma.
13. Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon
14. Sonic hedgehog hepatocellular adenoma: magnetic resonance imaging features and correlation with histology
15. Innervation of the proximal human biliary tree
16. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response
17. Repression of exosome secretion by mutated β-catenin contributes to immune escape in hepatocellular carcinoma
18. Loss of RND3/RHOE controls entosis through LAMP1 expression in hepatocellular carcinoma
19. New MRI features improve subtype classification of hepatocellular adenoma
20. Hepatocellular Adenomas: Morphology and Genomics
21. CYP1A2 is a predictor of HCC recurrence in HCV-related chronic liver disease: A retrospective multicentric validation study
22. Chapter 1 - Structure, Function and Responses to Injury
23. Hepatocellular nodules in vascular liver diseases
24. Supplementary Methods from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
25. Supplementary Figure Legend from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
26. Supplementary Figure 1 from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
27. Supplementary Figure 2 from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
28. Supplementary Table 1 from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
29. Supplementary Table 2 from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
30. Data from Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
31. Data from Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro
32. Supplementary Material and Methods, SUpplementary Figures 1-2, Supplementary Tables 1-5, Supplementary References from Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro
33. Data from Association of CYP1B1 Germ Line Mutations with Hepatocyte Nuclear Factor 1α–Mutated Hepatocellular Adenoma
34. Supplementary Table 1 from Association of CYP1B1 Germ Line Mutations with Hepatocyte Nuclear Factor 1α–Mutated Hepatocellular Adenoma
35. Antagonism between wild-type and mutant b-catenin controls hepatoblastoma differentiation via Fascin-1
36. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis
37. Strategies for a Successful Anatomic Pathology Subspecialty Workgroup: The 26-Year Collaboration of “The Elves”
38. Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders
39. List of Contributors
40. Benign Hepatocellular Tumors
41. Contributors
42. Structure, Function, and Responses to Injury
43. Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress
44. Hepatocellular adenoma management: Call for shared guidelines and multidisciplinary approach
45. Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma
46. Chapter 45 - Molecular Pathogenesis and Diagnostics of Hepatocellular Tumors
47. Hepatocellular adenomatosis: What should the term stand for!
48. Hepatitis B Virus Pregenomic RNA in Hepatocellular Carcinoma: A Nosological and Prognostic Determinant
49. Focal β‐catenin mutation identified on formalin‐fixed and paraffin‐embedded inflammatory hepatocellular adenomas
50. Reply
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.